MedTrace Logo

Comparison of Triflusal and Clopidogrel in Secondary Prevention of Stroke Based on the Genotyping

NCT01174693 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 795

Last updated 2015-03-17

No results posted yet for this study

Summary

The purpose of this study is to compare the preventive effect of stroke between triflusal and clopidogrel in ischemic stroke patient based on the cytochrome P450 2C19 (CYP2C19) polymorphism.

Conditions

  • Cerebral Infarction

Interventions

DRUG

Triflusal

Dose: 150mg or 300mg capsule, 300mg bid, Mode of administration: oral, Duration: from randomization to 31 December 2014

DRUG

Clopidogrel

Dose: 75mg tablet, 75mg once daily, Mode of administration: oral, Duration: from randomization to 31 December 2014

Sponsors & Collaborators

  • Myung In Pharmaceutical Company

    collaborator UNKNOWN

  • Yonsei University

    collaborator OTHER

  • Gangnam Severance Hospital

    lead OTHER

Principal Investigators

  • KyungYul Lee, MD, PhD · Gangnam Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2014-12-31
Completion
2015-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01174693 on ClinicalTrials.gov